Consensus Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 05/06/2026 BST			5-day change	1st Jan Change
73.09 ^USD	-2.75%		-6.19%	+10.09%

05-27	Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026	CI
05-26	Arrowhead Pharmaceuticals Presents New Positive Clinical Data for Plozasiran at the 94th European Atherosclerosis Society Congress	CI

Evolution of the Average Target: Arrowhead Pharmaceuticals, Inc.

Evolution of the Target Price: Arrowhead Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Arrowhead Pharmaceuticals, Inc.

95edcc97addd4f6b92b05f1c.N13vgdzXDUcx6OfK68pDr3fFHduUQ4rfTWOygULAscs.XRymuK2daRhzv4iuqv0k10CHMJb8CeWefCLXsgaL1P5waNznlYhodXfQog~c682567b0c0bfc27cf5c0868657f713b

Analysts' recommendations: Arrowhead Pharmaceuticals, Inc.

05-08	RBC Capital Adjusts Arrowhead Pharmaceuticals Price Target to $87 From $80, Maintains Outperform Speculative Risk Rating	MT
05-01	JPMorgan Initiates Arrowhead Pharmaceuticals at Overweight With $88 Price Target	MT
04-21	Morgan Stanley Upgrades Arrowhead Pharmaceuticals to Overweight From Equal Weight, Adjusts PT to $100 From $78	MT
01-22	B. Riley Raises Price Target on Arrowhead Pharmaceuticals to $101 From $61, Keeps Buy Rating	MT
01-07	Chardan Adjusts Price Target on Arrowhead Pharmaceuticals to $80 From $60, Maintains Buy Rating	MT
12-11	RBC Raises Price Target on Arrowhead Pharmaceuticals to $80 From $52, Keeps Outperform, Speculative Risk	MT
11-19	RBC Raises Price Target on Arrowhead Pharmaceuticals to $52 From $45, Keeps Outperform, Speculative Risk	MT
11-12	Arrowhead Has Large Market Opportunity With Severe Hypertriglyceridemia Treatment, Morgan Stanley Says	MT
11-12	Morgan Stanley Raises Price Target on Arrowhead Pharmaceuticals to $45 From $29, Keeps Equalweight Rating	MT
22/10/25	B. Riley Raises Price Target on Arrowhead Pharmaceuticals to $61 From $38, Keeps Buy Rating	MT
08/10/25	RBC Raises Price Target on Arrowhead Pharmaceuticals to $45 From $38, Keeps Outperform, Speculative Risk	MT
08/08/25	RBC Trims Price Target on Arrowhead Pharmaceuticals to $38 From $40, Keeps Outperform, Speculative Risk	MT
14/05/25	UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $63 From $71, Maintains Buy Rating	MT
13/05/25	RBC Adjusts Price Target on Arrowhead Pharmaceuticals to $40 From $42, Maintains Outperform Speculative Risk Rating	MT
14/02/25	B. Riley Adjusts Price Target on Arrowhead Pharmaceuticals to $38 From $51, Keeps Buy Rating	MT
12/12/24	B. Riley Lowers Price Target on Arrowhead Pharmaceuticals to $51 From $55, Keeps Buy Rating	MT
03/12/24	HC Wainwright Raises Price Target on Arrowhead Pharmaceuticals to $80 From $60, Keeps Buy Rating	MT
27/11/24	Analyst recommendations: Nvidia, Workday, Doordash, Nutanix, T-Mobile...
22/08/24	Analyst recommendations: Estee Lauder, Sentinelone, Snowflake, Wolfspeed, Admiral...
09/08/24	Analyst recommendations: Epam Systems, Five9, T-Mobile, Lyft, Under Armour...
23/07/24	Analyst recommendations: CrowdStrike, Johnson & Johnson, Netflix, Nvidia, Snap...
05/07/24	HC Wainwright Cuts Price Target on Arrowhead Pharmaceuticals to $60 From $90, Keeps Buy Rating	MT
10/05/24	UBS Cuts Price Target on Arrowhead Pharmaceuticals to $71 From $75, Keeps Buy Rating	MT
08/02/24	B. Riley Adjusts Arrowhead Pharmaceuticals' PT to $55 From $50, Keeps Buy Rating	MT
07/02/24	UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $75 From $78, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ARROWHEAD PHARMACEUTICALS, INC.					+20.63%
	ARGENX SE					+10.53%
	WUXI APPTEC CO., LTD.					+51.16%
	BIONTECH SE					+40.53%
	INSMED INCORPORATED					+111.76%
	WUXI BIOLOGICS (CAYMAN) INC.					+43.27%
	GENMAB A/S					+46.08%
	EXELIXIS, INC.					-5.79%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+39.21%
	SUMMIT THERAPEUTICS INC.					+92.65%
	Average					+45.00%
	Weighted average by Cap.					+41.26%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

73.09USD

Average target price

88.17USD

Spread / Average Target

+20.63%

High Price Target

110.00USD

Spread / Highest target

+50.50%

Low Price Target

46.00USD

Spread / Lowest Target

-37.06%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

RBC Capital Markets
JPMorgan Chase
Morgan Stanley
B. Riley
Chardan Research
UBS
HC Wainwright
BofA Securities
TD Cowen
Piper Sandler
SVB Securities LLC
Goldman Sachs
Bernstein
Baird
Jefferies & Co.
SVB Leerink
Chardan